Agreement with Max Delbrück Center Provides Access to Broad Intellectual Property Portfolio of Unique Humanized Antibody Fragments and Antigen-Binding Domains Targeting BCMA.
Ascenion GmbH, technology transfer partner of the Max Delbrück Center for Molecular Medicine (MDC), has negotiated an agreement between the MDC and Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The company has secured an exclusive option to an intellectual property portfolio owned by the MDC covering novel chimeric antigen receptor (CAR) constructs that specifically bind B-cell Maturation Antigen (BCMA). Under the agreement with MDC, Fate Therapeutics holds an exclusive option to exclusively license the portfolio for all cell products, including CAR NK- and T-cell products, derived from induced pluripotent stem cells (iPSCs).
Further information:
See <link https: ir.fatetherapeutics.com news-releases news-release-details fate-therapeutics-secures-exclusive-option-novel-humanized-anti _blank external-link-new-window>Fate’s press release
